A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
Latest Information Update: 20 Nov 2023
At a glance
- Drugs GSK 2647544 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 10 Oct 2016 Results of this and other study (NCT01978327) published in the International Journal of Clinical Pharmacology and Therapeutics
- 11 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2012 New trial record